Table 3 Associations of SNAP amplitudes with WM patient features.
| Patients with WM: features | SNAP amplitude (μV) | p | ||||
|---|---|---|---|---|---|---|
| Feature present | Feature absent | |||||
| History | ||||||
| Age > 60 years | 5.7 (0.6) | 8.3 (0.7) | 0.007 | |||
| Disease duration > 4 years | 5.5 (0.7) | 6.5 (0.6) | 0.2 | |||
| Treatment modality | ||||||
| Rituximab | 6.7 (0.8) | 6.2 (0.6) | 0.6 | |||
| Cladribine | 5.4 (1.0) | 6.8 (0.5) | 0.2 | |||
| Fludarabine | 6.6 (0.8) | 6.4 (0.5) | 0.8 | |||
| Cyclophosphamide | 7.5 (1.7) | 6.3 (0.5) | 0.4 | |||
| Plasma exchange | 4.9 (1.5) | 6.6 (0.5) | 0.3 | |||
| Clinical examination | ||||||
| Quantitative vibration ⩽ 4 | 4.8 (0.6) | 8.2 (0.6) | < 0.001 | |||
| Pin sensation reduced | 4.5 (0.7) | 7.4 (0.6) | 0.004 | |||
| Proprioception reduced | 3.0 (0.9) | 6.4 (0.5) | 0.01 | |||
| Tandem gait abnormal | 4.3 (0.9) | 7.6 (0.5) | 0.001 | |||
| Laboratory results | ||||||
| Total IgM > 20 g/l | 6.2 (0.6) | 5.7 (0.6) | 0.8 | |||
| Demyelinating features | 0.2 (0.2) | 6.5 (0.5) | <0.001 | |||
| Control patients | ||||||
| Age > 60 | 7.8 (0.7) | 11.0 (1.0) | 0.008 | |||